Your session is about to expire
← Back to Search
Local Anesthetic
Lidocaine IV vs. ESP Block for Rib Fractures (Rib Fract ESP Trial)
Phase 2
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
All adult patients admitted to Stanford Health Care with two or more acute traumatic rib fractures.
- All adult patients admitted to Stanford Health Care with two or more acute traumatic rib fractures.
Must not have
Hemodynamically instability
Polytrauma (defined as bone or organ injury outside the thorax)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 4 hours general pain scores, and baseline, 24 hours, 48 hour, 72 hours for pain scores with cough and inspiration.
Summary
This trial will compare the effectiveness of ESPB as an alternative method to the current standard of care at Stanford Health Care (SHC) for pain management in traumatic rib fractures.
Who is the study for?
This trial is for adults at Stanford Health Care with two or more acute traumatic rib fractures. It's not for those on mechanical ventilation, with lidocaine allergies or heart conduction problems, chronic opioid users, pregnant women, prisoners, unstable vital signs, or injuries beyond the chest area.
What is being tested?
The study compares pain management methods for rib fractures: continuous intravenous (IV) Lidocaine infusion versus a new nerve block called ESPB. The goal is to see which method better controls pain and improves breathing efforts after injury.
What are the potential side effects?
Possible side effects include allergic reactions to lidocaine such as rash or itching; nervous system issues like dizziness or seizures; and heart-related side effects including changes in blood pressure or irregular heartbeat.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have two or more broken ribs from a recent injury.
Select...
I have two or more broken ribs from a recent injury.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My blood pressure and heart rate are stable.
Select...
I have injuries to bones or organs outside my chest area.
Select...
I am allergic to local anesthetics or have specific heart conditions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 4 hours general pain scores, and baseline, 24 hours, 48 hour, 72 hours for pain scores with cough and inspiration.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 4 hours general pain scores, and baseline, 24 hours, 48 hour, 72 hours for pain scores with cough and inspiration.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
OME consumption at 24 hours of treatment.
Secondary study objectives
Incentive spirometry volumes (volume of 0 - 5000 mL)
Inflammatory biomarkers
Length of hospital stay
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment ArmExperimental Treatment1 Intervention
10 mL of 2% lidocaine via ESPB
Group II: Control ArmPlacebo Group1 Intervention
1.0mg/kg/hr IV lidocaine infusion
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,487 Previous Clinical Trials
17,516,583 Total Patients Enrolled
5 Trials studying Rib Fractures
190 Patients Enrolled for Rib Fractures
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My blood pressure and heart rate are stable.I have injuries to bones or organs outside my chest area.I have two or more broken ribs from a recent injury.I am allergic to local anesthetics or have specific heart conditions.I have two or more broken ribs from a recent injury.
Research Study Groups:
This trial has the following groups:- Group 1: Control Arm
- Group 2: Treatment Arm
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.